PHLDA2 and nonpapillary renal cell carcinoma: Eventually, using data derived from three RCTs, we confirmed that elevated PHLDA2 expression could robustly predict worse therapeutic efficacy of ICI plus anti-angiogenic agent combination therapy in ccRCC.